The European Hematology Association (EHA)

Nikhil Munshi would like to see more emphasis put into studies to provide reasonable costs for treatment so as to relieve the financial burden of some patients. Read More ›

Nikhil Munshi believes caregivers should be informed about the newer medicines so they can be aware of potential side effects as well as medicine's responsibility to take a holistic approach to patients' lives post-treatment. Read More ›

Joseph Connors, MD, explains how the understanding of the disease has evolved leading to the categorization of subsets and consequently resulted in the development of newer therapies to address these subsets. Read More ›

Leaders in hematology will present data from 6 research efforts that have been recognized as top abstracts in this year’s Congress. Leukemias – acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) –feature prominently. Read More ›

This poster session spotlights clinical trial data for commercialized and emerging therapies with activity in adults and children with acute lymphoblastic leukemia (ALL). Novel therapies include inotuzumab ozogamicin, ponatinib, and bortezomib. Read More ›

Several targeted agents are recently available or in late-stage development for patients with chronic lymphocytic leukemia (CLL), including ibrutinib, venetoclax, ublituximab, and TGR-1202. Efficacy and safety data from clinical trials and real-world studies will be shared in this evening poster session. Read More ›

CAR T cells are generating impressive outcomes in acute lymphoblastic leukemia (ALL) and other hematologic malignancies. This session highlights data regarding this novel approach, as well as improved methods for prognosticating patient outcomes using minimal residual disease findings. Read More ›

Immuno-oncology agents, particularly checkpoint inhibitors, are altering treatment paradigms in multiple solid and liquid tumors. Nivolumab (NIVO) was recently indicated for use in patients with relapsed Hodgkin lymphoma, representing the first approval of checkpoint inhibitors in a hematologic malignancy. Researchers report early but intriguing findings regarding use of NIVO and 5-azacitidine in adults with relapsed acute myeloid leukemia (AML).

Read More ›

Venetoclax, a selective oral BCL-2 inhibitor, is approved in the United States for use in patients with high-risk chronic lymphocytic leukemia (CLL) after 1 prior therapy. Studies evaluating the role of venetoclax in combination with anti-CD20 antibodies and other agents used for CLL represent the next step in the agent’s evolution. Using post hoc analysis, this study compares outcomes associated with venetoclax monotherapy to venetoclax combined with rituximab in relapsed CLL.

Read More ›

Ibrutinib, the first commercialized inhibitor of Bruton’s tyrosine kinase, is now approved for first-line use in patients with chronic lymphocytic leukemia. Because patients enrolled in clinical trials, as well as the level of monitoring in trials, do not always reflect community-based oncology practice, it is critical to evaluate data from large patient registries to learn if outcomes are reproducible in the real world.

Read More ›